Glenn Pierce, M.D., Ph.D has more than 35 years of experience in bench-to-bedside research and development with several public and private biopharmaceutical companies, including Biogen, Bayer, Inspiration, Avigen, Selective Genetics, and Amgen. At Biogen, Dr. Pierce served as senior vice president of hematology, cell and gene therapies, with overall R&D responsibility for hemophilia and hemoglobinopathies and led the research and clinical development of the first extended half-life FVIII (Factor VIII) and FIX (Factor IX) Fc fusions. He has also been involved in the R&D for 5 additional commercialized products for hemophilia. He co-founded Ambys Medicines, a cell and gene therapy liver regeneration start-up, where he served as the CMO and most recently served as interim CSO of Voyager Therapeutics, a neurodegenerative gene therapy company, where he serves on the board of directors.

Dr. Pierce currently serves as vice president, medical, with the World Federation of Hemophilia (WFH). He serves on the U.S. medical and scientific advisory council (MASAC), and previously served on the board of directors and as board president of the National Bleeding Disorders Foundation (NBDF) (previously NHF). Dr. Pierce spearheaded the initiation of the expanded WFH humanitarian aid program providing therapeutics to over 30,000 people with hemophilia in 74 lower income countries. He also co-developed the My Life Our Future (MLOF) program in the U.S. to genotype more than 10,000 individuals in the U.S. bleeding disorder community. He currently consults for a number of next generation gene therapy companies in hemophilia and other therapeutic areas. Glenn was born with severe hemophilia A and was cured in 2008.